Spain Still Blocks Access to New Alzheimer’s Drugs Over Pricing and Clinical Value Disputes
Access to Alzheimer’s Treatments Stalled in Spain Following Pricing Deadlock Patients in Spain continue to face delays in accessing new Alzheimer’s disease medications after the Interministerial Commission on Pharmaceutical Prices rejected the inclusion of two key drugs in the public health system. Despite approval in Europe, Spanish health authorities have deemed the clinical benefits of … Read more